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Abstract 
Background 
Rodent kindling induced by pentylenetetrazole (PTZ) is an established model of 
epileptogenesis and antiepileptic drug (AED) testing. Recently, a Drosophila systems 
model has been described in which chronic PTZ causes a decreased climbing speed in 
adult males on 7th day. Some AEDs ameliorate development of this locomotor deficit. 
Time-series of microarray expression profiles of heads of flies treated with PTZ has been 
found to resemble transcriptomic alterations associated with epileptogenesis. In the fly 
model, withdrawal from seven day long PTZ treatment causes an increased climbing 
speed on 7th consequent day. Here, we present a systems model of the post-PTZ 
withdrawal regime. 
 
Results 
Unlike AED-untreated individuals, flies treated with any of the five AEDs after PTZ 
discontinuation exhibited normal climbing speed on 7th day, i.e., 14th day from the 
beginning of PTZ treatment. Time-series of microarray expression profiles of fly heads 
comparing control PTZ- and AED-untreated, and AED-untreated post PTZ withdrawal 
groups showed differentially expressed genes throughout. These genes enriched gene 
ontology (GO) molecular functions including transcription regulator and GTPase 
regulator activities. Interestingly, expression profiles of fly heads comparing control 
PTZ- and AED-untreated, and AED-treated post PTZ withdrawal groups showed 
neutralization of transcription regulator and GTPase regulator activities by the AEDs. 
Further transcriptomic analysis based on overinteraction in protein interactome and 
enrichment of miRNA targets implicated axon guidance and neuronal remodeling related 
perturbations in the fly model.  
 
Conclusions 
Differential expression of genes belonging to transcription regulator and GTPase 
regulator activities have previously been reported in post-epileptogenesis in established 
rodent models. Also, axon guidance and neuronal remodeling related alterations have 
been implicated in epilepsy. The Drosophila model thus provides a unique opportunity to 
dissect long-term plasticity relevant in epileptogenesis at cellular and molecular levels. 
Besides, the model also offers an excellent system to efficiently screen agents with 
potential therapeutic activity. 
 
 
 
 
Background 
Epileptogenesis, the process of epilepsy development, is a network problem that may 
involve molecular, structural, and functional alterations in the brain.  It is poorly 
understood in cellular and molecular terms [1, 2]. Overlapping pathophysiological 
mechanisms are considered to underlie epilepsy and various other neurological and 
psychiatric conditions [3, 4]. Besides epilepsy, AEDs are also used in treating these other 
nonepileptic conditions [3, 5, 6]. Rodent kindling induced by PTZ is one of the 
established models of epileptogenesis and AED testing [7]. Repeated injection of a 
subconvulsant dose of the GABA antagonist over several weeks results in partially and 
fully kindled animals with the latter group showing clonic-tonic seizures; once kindled, 
the state of behavioral hyperexcitability persists for up to several weeks after 
discontinuing PTZ [8, 9]. Understanding epileptogenesis at systems level may facilitate 
development of novel antiepileptogenic, disease-modifying, and neuroprotective agents 
[10]. The inherent complexity of mammalian brain however precludes systems modeling 
of epileptogenesis in rodents [10]. 
 
Recently, a Drosophila systems model of PTZ induced locomotor plasticity responsive to 
AEDs has been empirically developed [11]. Altered locomotor activity is one of the 
kindling and post-kindling behavior in rats and mice [12, 13]. Also, locomotor behavior 
of Drosophila adults has been used previously to model neuropsychiatric conditions [14]. 
Given this, the fly PTZ model is considered useful in understanding processes relevant in 
epileptogenesis and in testing AEDs [11]. In one aspect of this model, seven days of PTZ 
treatment causes a decrease in climbing speed of adult male flies. Concomitant treatment 
with the AEDs sodium valproate (NaVP) or levetiracetam (LEV), not ethosuximide 
(ETH), gabapentin (GBP) or vigabatrin (VGB), suppresses appearance of decreased 
climbing speed on 7th day [11]. Time-series of microarray expression profiles has 
revealed wide-spread transcriptomic alterations in the head of PTZ treated flies [11]. The 
convulsant drug mainly downregulated gene expression, with affected genes 
overrepresenting various GO biological processes like transcription, neuron 
morphogenesis during differentiation, synaptic transmission, regulation of 
neurotransmitter levels, neurogenesis, axonogenesis, protein modification, axon 
guidance, actin filament organization etc. [11]. Proteomic interactome based analysis has 
provided directionality to these events [11]. Further, pathway overrepresentation analysis 
has revealed enrichment of Wnt signaling and other associated pathways in genes 
downregulated by PTZ. Most importantly, mining of available genetic, transcriptomic or 
proteomic data pertaining to Drosophila seizure mutants, established rodent 
epiletogenesis models or human epileptic patients has shown overrepresentation of 
epilepsy associated genes in the PTZ regulated set in the fly model [11]. The post-PTZ 
withdrawal regime of the fly model has not been characterized. Here, we describe the 
behavioral and transcriptomal pharmacology of this regime. Our results suggest that post-
PTZ withdrawal regime models post-epileptogenesis. 
 
 
 
 
 
Methods 
Fly behavior and drug treatment 
Previously described [11] methods were used. In brief, 3-4 days old unmated males were 
first treated with 8 mg/ml of PTZ for 7 days and then shifted to drug free media for 7 
days for climbing speed measurements, and for 1, 3 or 7 days for time-series microarray 
gene expression analysis. For the last time-point, flies were shifted to drug free media for 
three days and then again to vials containing fresh batch of drug free media. Flies treated 
with normal food (NF) were used as controls. The above three time-points correspond to 
8th, 10th and 14th days from the beginning of PTZ treatment, in that order. In AED 
treatment after withdrawing PTZ, flies were treated for first 3 days with an AED, i.e., up 
to 10th day, and the next four days with NF. Climbing speed was measured at the end, i.e., 
on 14th day of the beginning of PTZ treatment. Climbing speed was measured at the end, 
i.e., on 14th day of the beginning of PTZ treatment. Control flies (NF) were never 
exposed to any drug. Whereas climbing speed was measured only on 14th day, the 
expression profiles were generated for 10th and 14th day flies. Final concentration of PTZ, 
ETH, NaVP, GBP, VGB (all from Sigma-Aldrich) and LEV (Levesam 500, Nicholas 
Piramal) in the fly medium was 8, 3.48, 0.33, 16, 24 and 5 mg/ml, in that order. Climbing 
speed was measured using an indigenously developed semi-manual method that was 
validated by Dynamic Image Analysis System (DIAS v. 3.4.2, Soll Technologies) [11]. 
Student’s t-test, with Bonferroni corrected p-values, was used in the statistical analysis of 
climbing speed. 
 
Microarray profiling and data analysis 
Previously described [11] methods were performed. Total cellular RNA was isolated 
from fly heads belonging to four biological replicates. Microarray -cDNA Synthesis Kit, -
Target Purification Kit, and -RNA Target Synthesis Kit (Roche) were used to generate 
labeled antisense RNA. Starting with 10 µg of total cellular RNA, Eberwine method (kits 
from Roche) was used to generate cDNA and thereafter Cy3 and Cy5 (Amersham) labeled 
antisense RNA. The Cy3 and Cy5 labeled aRNAs (control and treated) were pooled 
together and precipitated, washed, air-dried, and dissolved in 18MΩ RNAase free water. 
A total of 52 microarrays (12Kv1, 44 nos.; 14Kv1, 8 nos.; CDMC) were hybridized, four 
each for 8th day and 7th day of PTZ treatment. Out of four, two slides were dye-swaps. 
Slides were scanned at 10 µm resolution using GenePix 4000A Microarray Scanner 
(Molecular Devices) and the images preprocessed and quantified using Gene Pix Pro 6.0 
(Molecular Devices). Ratio based data normalization and selection of features were 
performed using Acuity 4.0 (Molecular Devices). All Spots with raw intensity less then 
100U and less then twice the average background was ignored during normalization. 
Normalized data was filtered for the selection of features before further analysis. Only 
those spot were selected which contained a small percentage (<3) of saturated pixels, 
were not flagged bad or found absent (flags>0), had relatively uniform intensity and 
uniform background [Rgn R2 (635/532)>0.6] and were detectable above background 
(SNR>3). Analyzable spots in at least three of four biological replicates performed were 
retrieved for downstream analysis using Significant Analysis of Microarrays (SAM 3.0, 
Excel Add-In) [15], under the conditions of one class response and 100 permutations. 
Normalized log2 ratio (635/534) of four biological replicates with balanced dye-swaps 
was used for clustering. 
 Microarrays were clustered using Acuity 4.0 (Molecular Devices). Gene symbols and 
FlyBase IDs against CG numbers were retrieved using FLIGHT 
(http://www.flight.licr.org/search/batch_genes.jsp) and GeneMerge 
(http://genemerge.bioteam.net/convertgenenames.html), respectively. GOTool Box [16] 
was used to retrieve overrepresented biological processes in up- or down- regulated 
genes, under the settings, ontology, biological process or molecular function; mode, all 
terms; reference, genome; evidence, all-all evidence; species, D. melanogaster; GO-stats; 
statistic test, hypergeometric (http://burgundy.cmmt.ubc.ca/GOToolBox/). Molecular 
functions overrepresented at hypergeometric distribution probability <0.05 after 
Bonferroni correction for multiple hypothesis testing were considered significant in the 
unbiased analysis. The protein interactome database BioGRID v 2.0 
(http://www.thebiogrid.org/index.php) [17] was used in conjunction with the 
visualization software Osprey v. 1.2.0 (http://biodata.mshri.on.ca/osprey/servlet/Index) 
for examining overinteraction. The interactome database consisted of 7358 genes 
(vertices) and 24984 connections (edges). Overinteraction at hypergeometric distribution 
probability <0.05 after Bonferroni correction for multiple hypothesis testing was 
considered as significant. Enrichment for miRNA-target genes were analyzed using 
EMBL’s 2005 database (http://www.russell.embl-heidelberg.de/miRNAs/). As with 
protein interactome data, the software platform Osprey v. 1.2.0 was used for visualizing 
miRNA-target network. The miRNA-target database consisted of 4220 genes and 56 mi-
RNAs. Target enrichment at hypergeometric distribution probability <0.05 after 
Bonferroni correction was considered as significant. 
 For specifically examining enrichment of the GO biological process “axon guidance”, 
GOTool Box [16] was used as above except that Bonferroni correction was not applied. 
Human homologs of fly genes were identified using HomoloGene 
(http://www.ncbi.nlm.nih.gov/). Human homologs of axon guidance genes were depicted 
in the KEGG pathway for Homo sapiens 
(http://www.genome.jp/kegg/tool/color_pathway.html) because of unavailability of 
Drosophila pathway.  
 
Results and Discussion 
PTZ withdrawal induced behavioral alteration is ameliorated by AEDs 
Flies were treated with PTZ for 7 days, with AED for 3 days, and with drug free media 
for 4 days in chronological order, before climbing speed was measured. Flies treated with 
NF throughout served as controls. As reported earlier [11], PTZ withdrawal resulted in an 
enhanced speed (Figure 1). Notably, each of the five AEDs used ameliorated 
development of the PTZ withdrawal induced climbing abnormality (Figure 1). The 
climbing assay thus demonstrated that ETH, NaVP, LEV, GBP and VGB are all effective 
in post withdrawal model. This was in contrast to previously described chronic PTZ 
model in which only NaVP and LEV, not ETH, GBP and VGB, were found to be 
effective in ameliorating reduction in climbing speed caused by the convulsant drug [11]. 
In rodent epilepsy model, PTZ kindling is induced by repeated injection of the GABA 
antagonist over several weeks, resulting in partially and fully kindled animals; once 
kindled, the state of behavioral hyperexcitability persists for up to several weeks after 
discontinuation of PTZ treatment [18, 19]. The pharmacology of kindled and postkindled 
rodent epilepsy models is known to differ [20]. It was thus notable that the fly model 
showed different behavioral pharmacology between chronic PTZ treatment and post-PTZ 
withdrawal regimes. 
 
PTZ withdrawal induced transcriptomic alteration 
We generated expression profiles of fly heads at three time points – 1st, 3rd and 7th day 
after PTZ withdrawal, i.e., on 8th, 10th and 14th day from the start of PTZ treatment. These 
time-points represented beginning, latent, and behaviorally expressive phase of post-PTZ 
withdrawal, in that order. The full microarray data set has been deposited in the Gene 
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession series 
GSE7156. Clustering of microarrays showed the beginning phase behaving as an out-
group (Figure 2). A dynamic change in the transcriptome was thus found to underlie the 
fly model. We next identified differentially expressed genes. Previously, control 
microarray experiment comparing NF versus NF treated flies using the method used here 
was reported to detect no differentially expressed gene below 96% False Discovery Rate 
(FDR) [11]. In the present microarrays, we used a cut-off of 15% FDR (for gene lists, 
see additional file 1). In a time-series, differentially expressed genes in adjacent time-
points would be expected to match significantly in a direction-specific manner. We 
examined this using hypergeometric distribution probability of overlap, assuming 
population sizes of 10000, approximately the number of unique genes in the arrays. 
Whereas 8th and 10th day genes did not match significantly, a direction specific match 
was indeed observed between 10th and 14th day. The up- and down-regulated genes in 
these later time-points showed significant overlap, with p values of 1.72E-09 and 3.23E-
11, respectively. Further analysis showed enrichment of several GO molecular functions 
in differentially expressed genes at these two time-points (Table 1). Overall, post-PTZ 
withdrawal regime was characterized by upregulation of genes overrepresenting 
transcription regulatory (Figure 3) and GTPase regulator activities, and downregulation 
of genes enriched in protein binding, oxidoreductase and electron carrier activities. It was 
interesting to note here the already existing gene expression evidence for upregulated G-
protein signaling and transcriptional regulation activities during post-epileptogenesis in 
rodent models [21-24]. 
 
Amelioration of PTZ withdrawal induced transcriptomic alteration by AEDs 
Since AEDs ameliorated development of locomotor abnormality post-PTZ withdrawal 
(Figure 1), it was of interest to examine if AEDs act through G-protein signaling and 
transcriptional regulation in our fly model. For this, we generated microarray expression 
profiles of flies treated with AEDs post-PTZ withdrawal. Flies were treated with PTZ for 
seven days, following which they were first treated for 3 days with ETH, GBP, VGB, 
NaVP or LEV and then with drug free media for next four days. Microarray expression 
profiles of heads were generated from flies collected on 10th and 14th day from the 
beginning of PTZ treatment. Clustering of expression profiles was found to be consistent 
with the time-points (Figure 4). This suggested similarity in AEDs’ action. The full 
microarray data set has been deposited in the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) under accession series GSE10984 (ETH), GSE10985 
(GBP), GSE10986 (NaVP), GSE10987 (VGB) and GSE10988 (LEV). Differentially 
expressed genes in AED expression profiles were retrieved at 15% FDR cut-off (for gene 
lists, see additional file 2). Genes were predominantly downregulated by AEDs. Further 
analysis showed enrichment of various GO molecular functions in the differentially 
expressed genes (Table 2). Whereas these functions included oxidoreductase and 
electron carrier activities found enriched in AED-untreated group (Table 1), it was 
striking that unlike the latter none of the AED-treated group showed overrepresentation 
of transcription regulatory and GTPase regulator activities. Altogether, our transcriptomic 
analysis suggested that post-PTZ withdrawal induced alterations in transcription 
regulatory and GTPase regulator activities are ameliorated by AEDs. Interestingly, 
microarray expression profiling of rat brain has previously shown that NaVP regulates 
transcription regulatory and G-protein signaling [25]. Cumulatively, our results suggested 
that post-PTZ withdrawal in Drosophila models post-epileptogenesis. 
 
Protein interactome and miRNA-target based analyses of post-PTZ withdrawal genes 
We next used the available protein interactome map of Drosophila [17] to examine if it 
can provide directionality to gene expression changes (additional file 1) post-PTZ 
withdrawal. For this, we first analyze differentially expressed 10th day genes under the 
GO categories transcription regulator activity and GTPase regulator activity (Table 1) for 
overinteraction. Out of total 78 genes under these categories, 31 showed one or more 
interacting partners within the entire set of differentially expressed post-PTZ withdrawal 
time-series genes. Considering the total number of genes in the database as 7358, two of 
the 31 genes tested, the GTPase activating protein RanGap (CG9999) and the 
transcription factor ovo (CG6824), showed significant overinteraction. Interacting with 
each other, these genes showed three and four partners, respectively. Considering six and 
11 total interacting partners in the database, these interactions were significant 
(hypergeometric distribution p=0.046 and 0.027, Bonferroni adjusted, in that order). 
Considering this finding as important, we segregated all the seven unique interacting 
partners in the RanGap and ovo sub-network on post-PTZ withdrawal time scale. These 
seven genes spread to all the three time-points (Figure 5). They are highly conserved 
genes. For example, all except ovo has a human homolog - KRAS (Ras85D), RANGAP1 
(RanGap), DHX9 (mle), TCF7L2 (pan), PELI2 (Pli), and LMO4 (CG5708). The 
beginning time-point mammalian homolog KRAS maps to various pathways implicated in 
epileptogenesis - axon guidance, long-term depression, and MAPK signaling [26-28]. 
Although the rest of the five homologs did not map to these pathways, it is notable that 
the last time-point homolog LMO4 has recently been found to interact with a small 
GTPase activating repulsive guidance molecule [29]. Also, downregulation of LMO4 has 
been shown to neutralize repulsive activity of the molecule [29]. To test the hypothesis 
that axon guidance abnormality underlies our post-PTZ withdrawal model, we examined 
GO biological process enrichment in differentially expressed genes at all three time-
points combined together (additional file 1). Remarkably, axon guidance was one among 
several other processes such as neurogenesis, axonogenesis etc., that showed enrichment 
(for process list, see additional file 3). Both up- and down-regulation of axon guidance 
genes was observed (Table 3). Notably, many of the processes enriched in our model 
including axon guidance are known to be associated with rodent models of kindling 
epilepsy and status epilepticus [30]. In the axon guidance pathway, membrane receptors 
predominantly represented differentially expressed genes (Figure 6). Notably, axon 
guidance receptors have been implicated in rodent epilepsy models [31, 32]. Overall, 
protein-interaction analysis provided evidence for an altered axon guidance pathway in 
the post-PTZ withdrawal model.  
 
Most of the axon guidance genes belonged to 10th day time-point (Table 4). All of them 
were upregulated. To further test the axon guidance hypothesis, we used available 
miRNA-target database and examined if 10th day upregulated axon guidance genes are 
enriched for miRNA-targets. A total of 38 miRNA showed one or more targets in the 
gene set. Significant enrichment of targets was observed for mir-34 (Figure 7). Of the 
total 14 10th day genes, five were the targets of mir-34. Considering 178 total mir-34 
targets in the database containing 4220 genes, this enrichment was significant 
(hypergeometric distribution p=0.006, Bonferroni adjusted). The miRNA mir-34 has 
previously been shown to be regulated by the steroid hormone ecdysone and the 
terpenoid juvenile in Drosophila [33]. Hormone-dependent rewiring of neurons is a 
conserved feature of brain development and plasticity [34]. Hormones are known to 
regulate adult behavior and associated neuronal plasticity in insects [34]. In human 
epilepsy also, steroid hormones are considered as pharmacoactive compounds influencing 
seizure threshold [35]. Given this, it was interesting to find mir-34 target enrichment in 
our model. Cumulatively, miRNA-target analysis supported a role of neuronal 
remodeling in post-PTZ withdrawal model. 
 
Conclusion 
We have presented here a novel Drosophila systems model. In this model, withdrawal 
from chronic PTZ results in locomotor alteration long after. Development of this 
behavioral alteration is ameliorated by AEDs. Transcriptomic characterization suggests 
altered expression of genes related to transcription regulator and GTPase regulator 
activities as causally associated with the fly model. Importantly, transcriptomic analysis 
of post-epileptogenesis rodent models has previously reported altered expression of genes 
related to these activities [21-25]. Given the transcriptomic similarity of previously 
described chronic PTZ Drosophila model with epileptogenesis [11], similarity of the 
present post-PTZ withdrawal part of the model with post-epileptogenesis is striking. 
Considering this, we have further analyzed our transcriptomic data at protein-interactome 
and miRNA-target levels. Our analyses implicate axon guidance and neuronal 
remodeling related perturbations in the fly model. Importantly, these alterations have 
previously been implicated in epilepsy [28, 30-32]. The Drosophila systems model thus 
seems to provide a unique opportunity to understand long-term plasticity of relevance in 
human conditions in cellular and molecular terms. Additionally, the model also offers an 
excellent system to efficiently screen agents with potential therapeutic activity. 
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Figure legends 
 
Figure 1. 
Amelioration of PTZ withdrawal induced locomotor alteration by AEDs. Mean ± S. 
E. (n=24) of climbing speed in flies treated in parallel. Speed in NF was compared with 
rest of the treatments. * indicates Bonferroni adjusted p values. Note that all five AEDs 
ameliorated climbing speed abnormality caused after PTZ withdrawal, except that VGB’s 
own speed lowering effect might be confounding. 
 
Figure 2. 
Time-series of head microarray gene expression profiles. Hierarchical clustering of 
microarray expression profiles generated from heads of flies harvested on 8th, 10th and 
14th day of beginning of PTZ treatment. City block similarity metric and average linkage 
methods were used for clustering of arrays. Note 8th day time-point as forming an out-
group. 
 
Figure 3. 
Enrichment of genes encoding transcription factors. Both basal and specific RNA 
polymerase II transcription factors were upregulated on 10th day. Members of the former 
category are shown here in the KEGG pathway. Red boxes represent upregulated genes. 
Grey and white boxes indicate other members of and absence of Drosophila 
melanogaster genes, respectively, in the pathway. 
 
Figure 4. 
Expression profiles associated with AED treatment. Hierarchical clustering of 
microarray expression profiles generated from heads of flies harvested on 10th and 14th 
day of beginning of PTZ treatment. City block similarity metric and average linkage 
methods were used for clustering of arrays. Note overall segregation between 10th and 
14th day time-points. 
 
Figure 5. 
Overinteraction among genes differentially expressed genes. The GTPase activating 
protein RanGap (CG9999) and the transcription factor ovo (CG6824) showed enrichment 
of interacting partners. The GTP-binding protein Ras85D (CG9375) was downregulated 
on 8th day; RanGap, ovo, the transcriptional regulators mle (CG11680) and pan 
(CG17964), and the kinase regulator Pli (CG5212) were upregulated on 10th day; the 
LIM domain containing gene CG5708 was downregulated on 14th day. 
 
Figure 6. 
Enrichment of axon guidance pathway in differentially expressed genes. Human 
homologs of time-series genes are represented in the KEGG pathway, as Drosophila 
pathway is not available. Green and red boxes represent down- and up- regulated genes, 
respectively. EphB and Ras represent 8th day, Sema5, Sema6, ITGB1 and CALN to 10th 
day, and Robo1 and Robo2 to 14th day. 
 
 
Figure 7. 
Enrichment of mir-34 targets in differentially expressed axon guidance genes post-
PTZ withdrawal. The axon guidance genes upregulated on 10th day showed 
overrepresentation of mir-34 targets. CG18497, transcription regulator spen; CG1560, 
membrane receptor mys; CG3401, GTPase betaTub60D; CG13906, transcriptional 
regulator nerfin-1; CG3340, transcription regulator Kr. 
Additional files 
 
Additional file 1. 
File format: .xls 
Title of data: Up- and down-regulated genes in fly heads on 8th, 10th and 14th day. 
Description of data: List of up- and down-regulated genes post-PTZ withdrawal. 
 
Additional file 2. 
File format: .xls 
Title of data: Up- and down-regulated genes in AED treated flies on 10th and 14th day. 
Description of data: List of up- and down-regulated post-PTZ withdrawal genes. 
 
Additional file 3. 
File format: .xls 
Title of data: Enriched GO processes in up- and down- regulated genes of 8th, 10th and 
14th day time-points combined. 
Description of data: List of significantly enriched processes in differentially expressed 
genes post-PTZ withdrawal. Corresponding nominal (unadjusted) p values and genes are 
given. 
Table 1. Enriched GO molecular functions in differentially expressed genes post-
PTZ withdrawal 
GO_ID TERM       p-value 
8th day downregulated 
GO:0005515 protein binding      0.003 
GO:0005488 binding       0.011 
GO:0017018 myosin phosphatase activity     0.047 
    
10th  day upregulated  
GO:0003702 RNA polymerase II  transcription factor activity  2.93E-06  
GO:0003704 specific RNA polymerase II transcription factor activity 6.96E-05 
GO:0030528 transcription regulator activity    0.0001 
GO:0030695 GTPase regulator activity     0.048 
    
14th day downregulated  
GO:0016491 oxidoreductase activity     0.003 
GO:0009055 electron carrier activity     0.005 
GO:0003824 catalytic activity      0.006 
Table 2. Enriched GO molecular functions in genes differentially expressed after 
AED treatment post-PTZ withdrawal 
GO_ID TERM       p-value 
10th day GBP downregulated  
GO:0009055 electron carrier activity     8.03E-07 
GO:0016491 oxidoreductase activity     9.43E-05 
GO:0008393 fatty acid (omega-1)-hydroxylase activity   0.003 
    
10th day VGB downregulated  
GO:0016491 oxidoreductase activity     5.39E-05 
GO:0003824 catalytic activity      4.00E-04 
    
10th day LEV upregulated  
GO:0009055 electron carrier activity     8.03E-07 
GO:0016491 oxidoreductase activity     9.43E-05 
GO:0008393 fatty acid (omega-1)-hydroxylase activity   0.003 
    
10th day LEV downregulated  
GO:0004035 alkaline phosphatase activity     0.013 
    
14th day GBP downregulated  
GO:0003824 catalytic activity      3.50E-07 
GO:0016491 oxidoreductase activity     4.58E-07 
GO:0009055 electron carrier activity     1.06E-05 
GO:0004568 chitinase activity      2.30E-02 
GO:0016877 ligase activity, forming carbon-sulfur bonds   3.60E-02 
 
14th day VGB downregulated  
GO:0003824 catalytic activity      1.71E-12 
GO:0016491 oxidoreductase activity     1.23E-07 
GO:0009055 electron carrier activity     0.004 
GO:0004866 endopeptidase inhibitor activity    0.006 
GO:0030414 protease inhibitor activity     0.009 
GO:0016462 pyrophosphatase activity     0.025 
GO:0016818 hydrolase activity, acting on acid      
  anhydrides, in phosphorus-containing anhydrides  0.028 
GO:0016817 hydrolase activity, acting on acid anhydrides   0.028 
GO:0004857 enzyme inhibitor activity     0.033 
GO:0017111 nucleoside-triphosphatase activity    0.044 
    
14th day NaVP downregulated  
GO:0003824 catalytic activity      1.14E-06 
GO:0009055 electron carrier activity     8.69E-06 
GO:0016491 oxidoreductase activity     0.0005 
GO:0008096 juvenile hormone epoxide hydrolase activity   0.017 
GO:0004568 chitinase activity      0.025 
GO:0004301 epoxide hydrolase activity     0.033 
    
14th day LEV downregulated  
GO:0005463 UDP-N-acetylgalactosamine transmembrane    
  transporter activity      0.005 
GO:0005456 CMP-sialic acid transmembrane transporter activity  0.005  
GO:0005464 UDP-xylose transmembrane transporter activity  0.009 
GO:0005461 UDP-glucuronic acid transmembrane transporter activity 0.009 
GO:0005459 UDP-galactose transmembrane transporter activity  0.023 
GO:0015165 pyrimidine nucleotide sugar transmembrane     
  transporter activity      0.033 
GO:0005338 nucleotide-sugar transmembrane transporter activity 0.037 
Table 3. Axon guidance genes differentially expressed post-PTZ withdrawal. 
Symbol  Full name 
8th day downregulated 
Pp1-87B  Protein phosphatase 1 
Galpha49B  G-protein-alpha[[q]] 
Sdc   Dsyndecan 
  
10th day upregulated  
ab   clueless 
Kr   kruppel 
Lim3   lethal(2)37Bd 
betaTub60D  beta-tubulin 
mys   lethal myospheroid 
lola   longitudinals absent 
Wnt5   wnt-oncogene-analog-3 
Sema-1a  semiphorin 
beat-Ia   triclops 
spen   rhinoceros 
stan   flamingo 
plexA   Plexin A 
Sema-5c  semiphorin 
nerfin-1  nerfin 1 
  
14th day upregulated  
lea   roundabout 2 
  
14th day downregulated  
Fas1   fasciclin I 
Hsc70-4  heat-shock protein 70 
stan   flamingo 
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